T56-LIMKi

924473-59-6

C19H14F3N3O3

DMSO : >= 36 mg/mL (92.47 mM)

Cell Cycle/DNA Damage

T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC₅₀ of 35.2 uM. IC50 & Target: IC50: 35.2 uM (Panc-1 cells)^[1] In Vitro: T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC₅₀ values of 18.3, 7.4, 35.2 and 90 uM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma^[1]. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 uM) reduces p-cofilin in a dose-dependent manner in NF1^?/?MEFs with an IC₅₀ of 30 uM. Notably, the inhibitor does not affect the amounts of total cofil. 50uM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers^[2]. In Vivo: T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control^[1].